Ignite Creation Date:
2025-12-24 @ 12:19 PM
Ignite Modification Date:
2025-12-29 @ 3:51 AM
Study NCT ID:
NCT05549661
Status:
RECRUITING
Last Update Posted:
2025-02-14
First Post:
2022-09-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Sponsor:
Mayo Clinic
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-04-04
Start Date Type:
ACTUAL
Primary Completion Date:
2027-06-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-09-19
First Submit QC Date:
None
Study First Post Date:
2022-09-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-02-12
Last Update Post Date:
2025-02-14
Last Update Post Date Type:
ACTUAL